Wellbutrin SR and XL Have Similar Anxiety Profiles
Based on FDA labeling data, Wellbutrin SR causes slightly more anxiety than Wellbutrin XL, though the difference is modest. In placebo-controlled trials for major depressive disorder, Wellbutrin SR at 300 mg/day caused anxiety in 5% of patients compared to 3% with placebo, while at 400 mg/day this increased to 6%. In contrast, Wellbutrin XL (150-300 mg/day) for seasonal affective disorder caused anxiety in 7% versus 5% with placebo 1.
Key Clinical Data from FDA Trials
The FDA labeling provides the most direct comparison:
Wellbutrin SR (Major Depressive Disorder):
- 300 mg/day: 5% anxiety vs 3% placebo
- 400 mg/day: 6% anxiety vs 3% placebo
- Agitation: 3% (300 mg) and 9% (400 mg) vs 2% placebo
- Insomnia: 11% (300 mg) and 16% (400 mg) vs 6% placebo 1
Wellbutrin XL (Seasonal Affective Disorder):
- 150-300 mg/day: 7% anxiety vs 5% placebo
- Agitation: 2% vs <1% placebo
- Insomnia: 20% vs 13% placebo 1
Understanding the Apparent Paradox
While XL shows higher absolute anxiety rates (7% vs 5-6% for SR), this likely reflects different study populations rather than formulation differences. The XL trials studied seasonal affective disorder patients who may have higher baseline anxiety, while SR trials enrolled major depression patients. The more clinically relevant finding is that both formulations show dose-dependent increases in anxiety and agitation 1.
Practical Clinical Implications
Start with lower doses regardless of formulation. Both SR and XL demonstrate that anxiety, agitation, and insomnia occur "especially shortly after initiation of treatment" 1. The SR data clearly shows dose-dependent effects: doubling from 300 to 400 mg/day nearly tripled agitation rates (3% to 9%) 1.
Avoid bupropion entirely in patients with pre-existing agitation. Guidelines explicitly state bupropion "should not be used in agitated patients" 2. This is a contraindication based on the drug's activating properties, not a formulation-specific concern.
Time the second SR dose before 3 PM to minimize insomnia risk, as recommended in treatment guidelines 2. XL's once-daily dosing may offer practical advantages for managing activation-related side effects through consistent drug levels.
Evidence on Anxiety Outcomes
Recent research challenges the traditional belief that bupropion worsens anxiety:
- A 2023 naturalistic study of 8,457 patients found no difference in anxiety outcomes between bupropion and SSRIs over 12 weeks when using propensity matching 3
- Multiple controlled trials show bupropion has comparable anxiolytic effects to sertraline in depressed patients with comorbid anxiety 4, 5
- A 2025 systematic review concluded bupropion provides "clinically relevant improvement in anxiety symptoms" with generally comparable efficacy to SSRIs, though SSRIs showed modest advantage in highly anxious subgroups 6
Common Pitfalls to Avoid
Don't assume XL is "safer" for anxiety-prone patients. The formulation difference primarily affects dosing convenience and pharmacokinetics, not the fundamental activating properties of bupropion. Both formulations carry the same warnings about agitation and anxiety 1.
Don't escalate doses rapidly. The SR data showing 3% agitation at 300 mg versus 9% at 400 mg demonstrates clear dose-response effects 1. Slow titration allows assessment of tolerability before increasing activation risk.
Don't overlook the timing advantage of SR. While XL offers once-daily convenience, SR's twice-daily dosing with the second dose before 3 PM provides a specific strategy to minimize insomnia 2, which often accompanies anxiety symptoms.
Bottom Line
Choose based on dosing convenience and patient adherence rather than anxiety concerns. The modest differences in anxiety rates between formulations (5-7% range) are clinically insignificant compared to the importance of proper dosing strategy. Start low (150 mg SR or XL), titrate slowly, time doses appropriately, and avoid use in overtly agitated patients regardless of formulation 2, 1.